Sort
30,917 grants matching “tumor microenvironment”
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
$588,065Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
$588,065Di Zhao · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Development of TGF-beta antagonists for cancer therapy
$587,809Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
An integrated approach to melanoma metastasis and therapy resistance: effects of age-related changes in the ECM and the biomechanics of the skin
$587,690Ashani T Weeraratna · Johns Hopkins University · R01 · FY2020 · CA
Targeting Aldehyde Dehydrogenase for Cancer Prevention
$587,645Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2023 · CA
Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments
$587,644Lisa J McCawley · Vanderbilt University · U01 · FY2017 · CA
Non-invasive imaging of the anti-tumor immune response
$587,640Novalia Pishesha · Boston Children'S Hospital · R01 · FY2025 · CA
Proj 3 - Targeting the Pro-tumorigenic Microenvironment
$587,566Yves A Declerck · Children'S Hosp Of Philadelphia · P01 · FY2020 · CA
Vermont Breast Cancer Molecular Characterization Laboratory
$587,560Janet L Stein · University Of Vermont & St Agric College · U01 · FY2020 · CA
Suppressing the Co-chaperone UNC45A reprograms the immunosuppressive tumor microenvironment to fight Cancer
$587,524Ahmed Chadli · Augusta University · R01 · FY2025 · CA
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer
$587,514Ashutosh Agarwal · University Of Miami School Of Medicine · U01 · FY2018 · CA
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
$587,453Xiaoguang Margaret Liu · Ohio State University · R01 · FY2022 · CA
Data-driven inference of regulators for cytokine-mediated tumor killing
$587,416Peng Jiang · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Fatty Acid Metabolic Regulation of Anti-Tumor Immunity Against Irradiated Glioblastoma
$587,406Claire Isabelle Vanpouille-Box · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · NS
Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
$587,394Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2024 · CA
Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity
$587,283Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2023 · CA
Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity
$587,283Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2022 · CA
Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer.
$587,277Rahul Suresh Shinde · Wistar Institute · R37 · FY2024 · CA
Trinity: Transcriptome assembly for genetic and functional analysis of cancer
$587,235Brian Haas · Broad Institute, Inc. · U24 · FY2022 · CA
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
$587,214David Andrew Largaespada · University Of Minnesota · R01 · FY2020 · NS
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
$587,169Xiaoguang Margaret Liu · Ohio State University · R01 · FY2023 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
$587,093John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Immune Responses in Otitis Prone Children
$587,036Michael E Pichichero · Rochester General Hospital (Ny) · R01 · FY2012 · DC
Analysis of the Role of Microenvironment and Stem Cells in Initiation, Progressio
$587,031Mina J Bissell · University Of Calif-Lawrenc Berkeley Lab · U54 · FY2009 · CA
Clinical, molecular, and immune characterization of naturally occurring osteosarcoma in dogs
$587,026Robert B Rebhun · University Of California At Davis · U01 · FY2025 · CA